Company intelligence / Profile preview

Hy2Care

Enschede, Overijssel, Netherlandshy2care.com ↗

Ownership: Private
Employees: ~13
Development stage: Phase 1

Overview

Hy2Care’s lead product, CartRevive hydrogel implant, is an injectable and bioresorbable hydrogel designed to fill and repair traumatic cartilage defects in the knee. The company has received FDA Investigational Device Exemption (IDE) approval to begin clinical evaluation in the US. Early studies support its potential as a minimally invasive alternative for functional recovery of joint cartilage, with ongoing preparations for pivotal trials and commercial expansion in Europe and globally.

Therapeutic areas: Rheumatology
Modalities: Hydrogel-based drug delivery therapyDevice (Implantable medical device)
Industry: Implantable Medical Devices

Drug pipeline

1 asset

CartRevive

Phase 1

Indications: Cartilage defects

Beyond the preview

Go deeper on Hy2Care.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hy2Care.

Explore the full profile